Proactive Investors - Run By Investors For Investors

Akari Therapeutics' stock flies after 'positive' FDA meeting for pediatric thrombotic microangiopathy

Pivotal clinical trial for Coversin in pediatric patients with HSCT-TMA expected to start in fourth quarter 2019 following FDA feedback
A researcher in a lab
New York-based Akari Therapeutics is a clinical-stage biopharmaceutical company, focusing on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases

Akari Therapeutics PLC (NASDAQ:AKTX) shares rocket Thursday after the company said it plans to start trials in European and US pediatric patients this year for its treatment of pediatric thrombotic microangiopathy (TMA), defined by low blood platelets, and organ damage due to the formation of microscopic blood clots in capillaries and arteries.

Investors sent shares of the company up 25.76% to $7.42 in midday trading.

New York-based Akari Therapeutics is a clinical-stage biopharmaceutical company, focusing on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases.

READ: Neovasc announces public offering, aims to raise almost US$4.25M

Its lead drug candidate is Coversin, a second-generation inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases.

Akari said it had a “successful,” pre-investigational new drug (IND) meeting with the Food and Drug Administration (FDA) regarding its pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

HSCT-TMA is an orphan condition with an estimated fatality rate of more than 80% in children

A framework for the trial design was agreed with the FDA. 

“Akari plans to commence a trial in European and US pediatric HSCT-TMA patients in the fourth quarter of 2019,” said Akari CEO Clive Richardson in a statement. “We see HSCT-TMA as a gateway indication into a range of other poorly treated orphan TMAs, and are enthusiastic about the potential of Coversin to offer an improved standard of care for patients with these rare and usually fatal conditions.”

—(This story was updated to reflect share price)— 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

 

 

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

marketing
January 29 2019
“With the geopolitical landscape remaining in flux, clients are looking for greater certainty from their marketing programmes which our agencies and data businesses are proving able to provide"
books
Wed
Here we take a closer look at Bloomsbury Publishing PLC (LON:BMY)
Augmented Reality on phone
March 21 2019
The firm currently has around nine companies in its portfolio that are either direct investments or through its sub-fund, Suir Valley Ventures, in which it holds a 22% stake
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use